OR WAIT null SECS
The funding will help advance the vaccine’s clinical evaluation, potential marketing authorization, development and manufacturing in Germany, and the number of participants in late-stage clinical trials.
BioNTech, an immunotherapy company, announced on Sept. 15, 2020 that it is receiving a grant of $444 million from the German Federal Ministry of Education and Research (BMBF) for further development of its COVID-19 vaccine program, BNT162.
According to a company press release, the funding will help advance the vaccine’s clinical evaluation and potential marketing authorization, while also expanding its development and manufacturing in Germany and the number of participants in late-stage clinical trials.
“We are grateful for the significant support from the BMBF, which is helping us to provide a safe and effective vaccine as soon as possible following regulatory approval,” said Ugur Sahin, MD, CEO and co-founder of BioNTech, in the press release. “The funding is an important contribution to accelerate the development and scaling-up of our COVID-19 vaccine manufacturing capacities in Germany. It highlights the tremendous importance of our mission to efficiently find a lasting solution to control the pandemic.”